Island Pharmaceuticals Ltd Cash Flow Conversion Efficiency

Latest as of June 2025: -0.237x

Island Pharmaceuticals Ltd cash flow conversion efficiency. Based on the latest financial reports, Island Pharmaceuticals Ltd (ILA) has a cash flow conversion efficiency ratio of -0.237x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-1.69 Million ≈ $-1.20 Million USD) by net assets (AU$7.16 Million ≈ $5.06 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Island Pharmaceuticals Ltd (2019–2024)

Cash flow conversion efficiency of Island Pharmaceuticals Ltd from 2019 to 2024. This chart illustrates how Island Pharmaceuticals Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Island Pharmaceuticals Ltd for real-time trading data and today's change.

Island Pharmaceuticals Ltd Cash Flow Conversion Ratio Explained

Island Pharmaceuticals Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Island Pharmaceuticals Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Island Pharmaceuticals Ltd ranked by their cash flow conversion efficiency. Also see how much is Island Pharmaceuticals Ltd worth for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
NeueHealth Inc NYSE:NEUE	0.007x
Haulotte Group SA PA:PIG	0.029x
Midsummer AB (publ) ST:MIDS	-0.108x
Kyungdong Gas KO:012320	0.000x
Hwang-Kum Stee KO:032560	0.014x
Stefstock JSE:SSK	-2.100x
Guillemot Corporation S.A. PA:GUI	-0.006x
Empery Digital Inc. NASDAQ:EMPD	-0.021x

Annual Cash Flow Conversion Efficiency for Island Pharmaceuticals Ltd (2019–2024)

The table below shows the annual cash flow conversion efficiency of Island Pharmaceuticals Ltd from 2019 to 2024. Review ILA FCF to total liabilities ratio to assess the company's free cash flow relative to its total liabilities.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	AU$7.16 Million ≈ $5.06 Million	AU$-2.77 Million ≈ $-1.96 Million	-0.387x	+81.44%
2023-12-31	AU$1.52 Million ≈ $1.07 Million	AU$-3.16 Million ≈ $-2.24 Million	-2.084x	-37.34%
2022-12-31	AU$1.79 Million ≈ $1.26 Million	AU$-2.71 Million ≈ $-1.92 Million	-1.517x	-248.92%
2021-12-31	AU$4.32 Million ≈ $3.06 Million	AU$-1.88 Million ≈ $-1.33 Million	-0.435x	-196.57%
2020-12-31	AU$6.40 Million ≈ $4.53 Million	AU$-938.24K ≈ $-663.86K	-0.147x	-702.06%
2019-12-31	AU$-657.00 ≈ $-464.87	AU$-16.00 ≈ $-11.32	0.024x	--

About Island Pharmaceuticals Ltd

AU:ILA Australia Biotechnology

Market Cap

$60.92 Million

AU$86.10 Million AUD

Market Cap Rank

#20948 Global

#705 in Australia

Share Price

AU$0.32

Change (1 day)

-1.54%

52-Week Range

AU$0.27 - AU$0.57

All Time High

AU$0.57